Board of Directors

Trevor Bezdek is one of our co-founders and has served as a member of our board of directors since our founding in September 2011. Mr. Bezdek was appointed as Chairman of the Board in April 2023. Previously, Mr. Bezdek was a Co-Chief Executive Officer and the Secretary of the Company from January 2015 to April 2023. Prior to that, Mr. Bezdek served as Managing Partner at Tryarc, LLC, an information technology consulting firm, from 2001 to 2007, and co-founded Biowire, a bioinformatics software provider and community for biologists and scientists. Mr. Bezdek holds a B.S. in Biological Sciences from Stanford University. We believe Mr. Bezdek is qualified to serve as a member of our board of directors because of his extensive experience in the healthcare, prescription medication and technology industries, in addition to the continuity he brings as one of our co-founders.

Douglas Hirsch is one of our co-founders and has served as a member of our board of directors since our founding in September 2011. Previously, Mr. Hirsch was a Chief Executive Officer of the Company from September 2011 to April 2023 and served as our Chief Mission Officer from April 2023 to October 2024. Prior to our founding, Mr. Hirsch served as Chief Executive Officer at DailyStrength, Inc., a provider of healthcare-focused online support groups, from March 2005 to November 2008, and previously held senior roles at Facebook, Inc. and Yahoo! Inc. Mr. Hirsch holds a B.A. in Political Science from Tufts University. We believe Mr. Hirsch is qualified to serve on our board of directors because of the historical knowledge, operational expertise, leadership, and continuity that he brings to our board of directors as our co-founder.

Christopher Adams has served as a member of our board of directors since October 2015. Mr. Adams is a Partner at Francisco Partners Management, L.P. (“Francisco Partners”), a global investment firm that specializes in partnering with technology and technology-enabled business, where he has served since August 2008. Prior to this, Mr. Adams was an associate at American Securities Capital Partners, a private equity firm, and a management consultant at Bain & Company, Inc. Mr. Adams also serves on the board of directors of several private companies. Mr. Adams holds a B.S. in Computer Engineering from the Georgia Institute of Technology and an M.B.A. from the Stanford Graduate School of Business. We believe that Mr. Adams is qualified to serve as a member of our board of directors because of his extensive experience in analyzing, investing in, and serving on the board of directors of several healthcare and technology companies from working in the private equity industry.

Dipanjan Deb has served as a member of our board of directors since October 2015. Mr. Deb is a co-founder of Francisco Partners, a global investment firm that specializes in partnering with technology and technology-enabled business, and has served as the Managing Partner and Chief Executive Officer of Francisco Partners since September 2005. Mr. Deb has also served as a Partner of Francisco Partners since its founding in August 1999. Prior to founding Francisco Partners, Mr. Deb was a principal at TPG Capital, a private equity firm, a Director of Semiconductor Banking at Robertson, Stephens & Company and a management consultant at McKinsey & Company, Inc. Mr. Deb has served on the board of directors of numerous public companies, including, most recently, LegalZoom.com, Inc. from August 2018 to June 2023, and currently serves on the board of directors of several private companies. Mr. Deb holds a B.S. in Electrical Engineering and Computer Science from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business. We believe that Mr. Deb is qualified to serve as a member of our board of directors because of his experience in the private equity and venture capital industries analyzing, investing in and serving on the boards of directors of manufacturing and technology companies.

Gregory Mondre has served as a member of our board of directors since October 2018. Mr. Mondre is Co-Chief Executive Officer and Managing Partner at Silver Lake Technology Management, L.L.C. (“Silver Lake”), a global technology investment firm. He joined Silver Lake in 1999 and most recently served as a Managing Partner and Managing Director of the firm from January 2013 to December 2019. Mr. Mondre currently serves on the board of directors of Motorola Solutions, Inc., a position he has held since August 2015 and where he also serves on its governance and nominating committee. He previously served as a director of Expedia Group, Inc. from May 2020 to October 2021 and of GoDaddy Inc. from May 2014 to February 2020. Mr. Mondre holds a B.S. degree in Economics from the Wharton School of the University of Pennsylvania. We believe Mr. Mondre is qualified to serve on our board of directors because of his significant experience in private equity investing and expertise in technology and technology-enabled industries.

Agnes Rey-Giraud has served as a member of our board of directors since June 2016. Ms. Rey-Giraud is the Founder and Chairman of Acera Surgical Inc., a bioscience company, where she served as the Chief Executive Officer from its founding in January 2013 until May 2022. Ms. Rey-Giraud previously served in multiple executive roles of increasing responsibility, including Executive Vice President and the President of International Operations, at Express Scripts Holding Company, a pharmacy benefit management organization. Ms. Rey-Giraud has served on the board of directors of UpHealth, Inc. since June 2021, where she is a member of its audit committee and nominating and corporate governance committee. Ms. Rey-Giraud also serves on the board of directors for several private companies. Ms. Rey-Giraud holds a B.S. and M.S. in Mechanical Engineering from Ecole Nationale d’Ingenieurs de Saint Etienne (ENISE), France, an MMa in Operations Management from Ecole de Management de Lyon (EM Lyon), France and an M.B.A. from the University of Chicago. We believe Ms. Rey-Giraud is qualified to serve on our board of directors because of her experience and expertise in the PBM industry gained as an executive of a large publicly traded company in that industry and her experience serving on the board of directors of several companies.

Kelly J. Kennedy has served as a member of our board of directors since December 2023. Since November 2023, Ms. Kennedy has served as the Chief Financial Officer of Willow Innovations, Inc., a women’s health technology company that develops and markets breastfeeding and wearable pumping products. She previously served as Executive Vice President, Chief Financial Officer of The Honest Company, Inc., a personal care company (the “Honest Company”), from January 2021 to September 2023. Prior to joining the Honest Company, Ms. Kennedy served as Chief Financial Officer of The Bartell Drug Company, a family-owned pharmacy chain, from September 2018 until its sale to Rite Aid in December 2020. Prior to that, Ms. Kennedy served as the Chief Financial Officer of Sur La Table, Inc. from June 2015 to September 2018, as the Chief Financial Officer of See’s Candies from January 2014 to June 2015 and as the Chief Financial Officer and Treasurer of Annie’s Inc. from August 2011 to November 2013. Ms. Kennedy has also served in various senior financial roles at Revolution Foods, Inc., Established Brands, Inc., Serena & Lily Inc., Forklift Brands, Inc., Elephant Pharm, Inc., Williams-Sonoma, Inc. and Dreyer’s Grand Ice Cream Holdings, Inc. Currently, Ms. Kennedy serves on the board of directors of Vital Farms, Inc., since December 2019, where she is the chair of its audit committee and a member of its compensation committee. Ms. Kennedy also currently serves on the board of directors of several private companies, including FirstFruits Farms LLC, since December 2019, RAD Power Bikes, Inc., since July 2021, and Skinny Mixes LLC, since July 2023. Previously, Ms. Kennedy served on the board of directors of the private company, Sur La Table, Inc., from September 2018 to November 2020. Ms. Kennedy received her M.B.A. from Harvard Business School and her B.A. in Economics from Middlebury College. We believe that Ms. Kennedy is qualified to serve on our board of directors because of her expertise in overseeing risk assessment management and financial reporting and her extensive experience with leading retail and consumer brands.

Simon Patterson has served as a member of our board of directors since May 2024. Mr. Patterson is a Managing Director at Silver Lake, a global technology investment firm, which he joined in 2005. Prior to joining Silver Lake, Mr. Patterson was a member of the founding management team of Global Freight Exchange Limited, a logistics software company acquired by Descartes Systems Group, and worked in various management roles at the Financial Times, a leading news organization. Mr. Patterson serves on the board of directors of several private companies and is a Trustee and Vice Chairman of The Royal Foundation of The Prince and Princess of Wales and a member of Mark Carney’s Panel of Senior Advisors at Chatham House. Previously, Mr. Patterson served on the board of directors of various public companies, including Dell Technologies Inc., a leading technology company, from October 2013 to September 2023, and Tesco plc, a multinational grocery and general merchandise retailer, from April 2016 to June 2022, where he was a member of its audit committee. He also served as a Trustee of the Natural History Museum in London. Mr. Patterson holds an M.A. from King's College, Cambridge University and an M.B.A. from the Stanford University Graduate School of Business, where he was an Arjay Miller Scholar and received the Alexander Robichek Award for Finance. We believe Mr. Patterson is qualified to serve on the Board because he has significant financial and management expertise and extensive experience in operating, advising and investing in technology and technology-enabled companies.

Ian T. Clark has served as a member of our board of directors since July 2024. Mr. Clark is an advisor to KKR & Co. Inc., a global investment firm. Mr. Clark formerly served as Chief Executive Officer, led the executive committee, and was a member of the board of directors of Genentech, Inc., a biotechnology company, from January 2010 until his retirement in December 2016. In total, he served for 14 years at Genentech, Inc. Before that, Mr. Clark served as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals, Inc. and G.D. Searle, LLC. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Kyverna Therapeutics, Inc., Olema Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Guardant Health, Inc. and Corvus Pharmaceuticals, Inc. Mr. Clark received his B.S. in Biological Sciences and an Honorary Doctorate of Science from Southampton University. We believe Mr. Clark is qualified to serve on our Board of Directors because of his extensive experience and expertise in the pharmaceutical and healthcare industries gained as an executive and director of multiple publicly traded and private companies operating in those industries.

Ronald E. Bruehlman has served as a member of our board of directors since November 2024. Since August 2020, Mr. Bruehlman has served as the Chief Financial Officer of IQVIA, a global provider of advanced analytics, technology solutions, and contract research, and has been with the company since October 2016. Prior to IQVIA, Mr. Bruehlman served as Chief Financial Officer of IMS Health from July 2011 to September 2016 and had a 23-year career at United Technologies Corporation, where he held multiple senior finance leadership roles of increasing responsibility. Mr. Bruehlman previously served on the board of directors of Atotech Ltd., Q-Squared Solutions, and Clipper Windpower. Mr. Bruehlman holds a B.S. in Economics from the University of Delaware, as well as an MBA in Finance from the University of Chicago, Booth School of Business. We believe Mr. Bruehlman is qualified to serve as a member of our board of directors because of his extensive expertise leading financial strategies for public and private healthcare and technology companies.

Board of Directors

site - Investor Tools